That's a tough call. I think that MNTA has set the bar high for everyone else. Fortunately, we can almost double our money just on the basis of no one else gaining approval for Enox.
Maybe MNTA can use some of its cash horde to fund an M-Copax clinical trial. However, from what DD and others have said, that will hopefully not be necessary.
Market Data 
Markets 
AI
